Compared to Novo Nordisks A/S (NYSE: NVO) Rybelsus, orforglipron appears to have multiple advantages
By addressing the root causes of weight gain and metabolic dysfunction, it helps patients maintain their progress over the long term
Its still progressing It does help control my A1C, but the only thing that has helped my HS is an antibiotic regimen and creams This certainly is not medical research, and the sample size is tiny, but the findings align with the limited research into how GLP-1 medications impact HS
All analyses were performed using linear mixed models with family-factor as random effect, in order to take into account the pedigree structure of the sample
Key findings: 12 mg dose: Average weight loss of 24.2% of body weight (approximately 58 lbs for a 240 lb individual) 8 mg dose: Average weight loss of 22.8% 4 mg dose: Average weight loss of 17.0% Placebo: Average weight loss of 2.1% Over 90% of participants receiving the 8 mg or 12 mg dose lost at least 10% of body weight Over 75% of participants at the highest dose lost at least 20% of body weight Significant improvements in waist circumference, blood pressure, and lipid profiles were observed across dose groups Phase 2 Trial in Type 2 Diabetes A separate phase 2 trial evaluated retatrutide in adults with type 2 diabetes and obesity (Rosenstock et al., Lancet , 2023)
Several factors influence IV therapy pricing and understanding them helps explain why prices vary so widely
